Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-09-29
Target enrollment:
Participant gender:
Summary
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the
side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib
hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small
cell lung cancer.